(Q38664198)

5 September 2017

Points for Consideration for dengue vaccine introduction - recommendations by the Dengue Vaccine Initiative (English)

1 reference

5 September 2017

0 references

Annelies Wilder-Smith

3

object named as

Annelies Wilder-Smith

1 reference

5 September 2017

Jacqueline Kyungah Lim

1

1 reference

5 September 2017

Yong-Seok Lee

2

1 reference

5 September 2017

Georges Thiry

4

1 reference

5 September 2017

Richard Mahoney

5

1 reference

5 September 2017

In-Kyu Yoon

6

1 reference

5 September 2017

10 December 2015

1 reference

Expert Review of Vaccines

5 September 2017

1 reference

5 September 2017

15

1 reference

5 September 2017

4

1 reference

5 September 2017

529-538

1 reference

The introduction of new vaccines into developing countries. V: Will we lose a decade or more in the introduction of dengue vaccines to developing countries?

5 September 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129279

Supporting new vaccine introduction decisions: lessons learned from the Hib Initiative experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129279

Preventing dengue--is the possibility now a reality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129279

Critical issues in dengue vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129279

Dengue vaccines: dawning at last?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129279

Dengue: challenges for policy makers and vaccine developers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129279

Dengue vaccine development: strategies and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129279

Challenges in the clinical development of a dengue vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129279

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129279

Challenges in the interpretation of dengue vaccine trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129279

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129279

Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129279

Preparing for dengue vaccine introduction: recommendations from the 1st dengue v2V International Meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129279

Preparing for dengue vaccine introduction in ASEAN countries: recommendations from the first ADVA regional workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129279

Strengthening vaccination policies in Latin America: an evidence-based approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129279

"Guidelines for the clinical evaluation of dengue vaccines in endemic areas": summary of a World Health Organization Technical Consultation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129279

Preparing for introduction of a dengue vaccine: recommendations from the 1st Dengue v2V Asia-Pacific Meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129279

Accelerating introduction of new vaccines: barriers to introduction and lessons learned from the recent Haemophilus influenzae type B vaccine experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129279

The impact of new vaccine introduction on immunization and health systems: a review of the published literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129279

Guidelines for clinical trials of dengue vaccine in endemic areas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129279

Long-term safety assessment of live attenuated tetravalent dengue vaccines: deliberations from a WHO technical consultation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129279

Will dengue vaccines be used in the public sector and if so, how? Findings from an 8-country survey of policymakers and opinion leaders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129279

New chapter unfolding in the fight against dengue with an unwritten ending.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129279

10.1586/14760584.2016.1129279

21 January 2018

Identifiers

DOI

1 reference

5 September 2017

1 reference